ATE224442T1 - Zielgerichtetes einbringen eines virus-vektors in säugetierzellen. - Google Patents

Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.

Info

Publication number
ATE224442T1
ATE224442T1 AT92922980T AT92922980T ATE224442T1 AT E224442 T1 ATE224442 T1 AT E224442T1 AT 92922980 T AT92922980 T AT 92922980T AT 92922980 T AT92922980 T AT 92922980T AT E224442 T1 ATE224442 T1 AT E224442T1
Authority
AT
Austria
Prior art keywords
pct
virus
virus vector
mammal cells
targeted introduction
Prior art date
Application number
AT92922980T
Other languages
English (en)
Inventor
Leif Lindholm
Sven Enerbaeck
Oerjan Strannegard
Original Assignee
Got A Gene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20384166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE224442(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Got A Gene Ab filed Critical Got A Gene Ab
Application granted granted Critical
Publication of ATE224442T1 publication Critical patent/ATE224442T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92922980T 1991-10-30 1992-10-28 Zielgerichtetes einbringen eines virus-vektors in säugetierzellen. ATE224442T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103183A SE503225C2 (sv) 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller
PCT/SE1992/000745 WO1993009221A1 (en) 1991-10-30 1992-10-28 Targeted delivery of virus vector to mammalian cells

Publications (1)

Publication Number Publication Date
ATE224442T1 true ATE224442T1 (de) 2002-10-15

Family

ID=20384166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92922980T ATE224442T1 (de) 1991-10-30 1992-10-28 Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.

Country Status (9)

Country Link
US (1) US5695991A (de)
EP (1) EP0614486B1 (de)
JP (1) JPH07502026A (de)
AT (1) ATE224442T1 (de)
CA (1) CA2122613C (de)
DE (1) DE69232782T2 (de)
ES (1) ES2180538T3 (de)
SE (1) SE503225C2 (de)
WO (1) WO1993009221A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US6261554B1 (en) 1995-07-25 2001-07-17 Introgene B.V. Compositions for targeted gene delivery
AU709831B2 (en) * 1995-11-13 1999-09-09 Takara Bio Inc. Method for gene transfer into target cells with retrovirus
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
WO1997038723A1 (en) * 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
DE19649645A1 (de) * 1996-11-29 1998-06-04 Hoechst Ag Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
AU737727B2 (en) 1997-04-10 2001-08-30 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
WO1998047916A1 (en) * 1997-04-18 1998-10-29 President And Fellows Of Harvard College Bifunctional polypeptides for cell-specific viral targeting
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
CA2318981A1 (en) * 1998-02-09 1999-08-12 Genzyme Corporation Nucleic acid delivery vehicles
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
US7078483B2 (en) * 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
US20060292121A1 (en) * 1998-04-29 2006-12-28 Hall Frederick L Retroviral vectors including modified envelope escort protein
AU4070499A (en) 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
US6060316A (en) * 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
EP1301612A2 (de) * 2000-05-31 2003-04-16 Genvec, Inc. Verfahren und zusammenfassung zur zielrichtung von adenoviralen vektoren
EP1372708B1 (de) 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Impstoffe zur transkutanen immunisierung gegen reisediarrhö
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US11266736B2 (en) 2008-04-17 2022-03-08 Vin De Bona Trading Company Pte Ltd Method of painting micro vesicles
WO2009127537A1 (en) 2008-04-17 2009-10-22 GÜNZBURG, Walter Post release modification of viral envelopes
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
EP3612556B8 (de) 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Verbesserte lamp konstrukte
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364934A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
DE68927996T2 (de) * 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
FR2649119A1 (fr) * 1989-06-30 1991-01-04 Centre Nat Rech Scient Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
EP1001032A3 (de) * 1989-08-18 2005-02-23 Chiron Corporation Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
AU660629B2 (en) * 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller

Also Published As

Publication number Publication date
ES2180538T3 (es) 2003-02-16
SE9103183D0 (sv) 1991-10-30
SE9103183L (sv) 1993-05-01
SE503225C2 (sv) 1996-04-22
CA2122613C (en) 2003-08-19
EP0614486B1 (de) 2002-09-18
EP0614486A1 (de) 1994-09-14
WO1993009221A1 (en) 1993-05-13
US5695991A (en) 1997-12-09
JPH07502026A (ja) 1995-03-02
CA2122613A1 (en) 1993-05-13
DE69232782T2 (de) 2003-02-20
DE69232782D1 (de) 2002-10-24

Similar Documents

Publication Publication Date Title
DE69232782D1 (de) Zielgerichtetes Einbringen eines Virus-Vektors in Säugetierzellen.
MY104946A (en) Antigen antibody conjugate.
GB2361921B (en) Herpes virus vectors for dendritic cells
EP0643131A3 (de) Vorrichtung zum Sammeln und in-vitro-Transport von Proben, insbesondere für Diagnoseverwendungen.
ES2034929T1 (es) Un sistema de transferencia de valores.
ES2161875T3 (es) Celulas con multiples epitopos alterados en un antigeno superficial para uso en transplantes.
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
DK0807178T3 (da) Mycobaktielle proteiner, mikroorganismer producerende samme og anvendelser af nævnte proteiner i vacciner og til påvisning af tuberkulose
PT649537E (pt) Imunoanalises para anticorpos anti-vhc utilizando antigenios com epitopos conformacionais
DE69021953D1 (de) Enzymimmuntest für Antigene und dafür verwendbare feste Phase.
NO932320D0 (no) Fremgangsmaate for paavisning av en analytt i en proeve og et utstyrsett for denne
TR26973A (tr) Bacillus thuringiensis cryie geni ve lepidoptera takimindan böceklere karsi zehirli protein.
MY100476A (en) Supported viral antigen and preparation and use thereof
ATE210753T1 (de) Mehrzweck-trägergerät
DE3378611D1 (en) Vaccine against dna viruses
Shang-Ying The Laoguanzhai and Ziba Religions During the Reign of Qianlung and their Anti-Qing Activities
SE9102014D0 (sv) Foerfarande i samband med mammalieceller
Deans Molecular and functional analysis of CD45 in T cell development
PT650523E (pt) Antigene cdw52 recombinante
HOJO Intensive Report from Respective Parts of Research on “Buddhism and Anthropology”
London Studies of the observed and theoretical variations of atmospheric ozone(Final Report, 1 Jan. 1977- 30 Jun. 1990)
IT1264078B1 (it) Uso di anticorpi anti-molecole hla classe i libere da beta-2 microglobulina per saggi di evidenziazione dell'esposizione al virus
IT9006602A0 (it) Test immunoenzimatico per la ricerca e determinazione degli anticorpi anti-ss-dna.
FR2653419B1 (fr) Dispositif pour le soulevement de charges et, notamment, pour le soulevement de meubles et de portes.
CS298787A3 (en) Micro-titrimetric plate for enzymoimmunological test for the detection of antibodies against nuclear antigen of epstain and barrow virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties